High Risk · 45/100Jul 14, 7:33 AM EDT
Summit Therapeutics Offloads C. Diff Drug to Biossil in Deal Worth Up to $105M
SMMT
Summit Therapeutics (SMMT) has agreed to sell its Phase 3 antibiotic ridinilazole, targeting Clostridioides difficile infections, to Canadian firm Biossil for up to $105 million. The deal provides Summit with a potential cash infusion while offloading a high-r…
- ▹Single-asset Phase 3 antibiotic sold for up to $105M, indicating limited pipeline depth; no FDA regulatory milestone yet, but Phase 3 data exists.
High Risk · 42/100Jul 14, 6:33 AM EDT
Spero Therapeutics Secures $105M Non-Dilutive Financing from KKR's Healthcare Royalty for Phase 2 Trial
SPROHCRXKKR
Spero Therapeutics (SPRO) has secured $105 million in non-recourse, non-dilutive financing from Healthcare Royalty (HCRX), a KKR (KKR) affiliate. The funds will primarily support the Phase 2 development of SP001, Spero's lead immunology candidate, a third-gene…
- ▹Non-dilutive financing reduces near-term dilution risk, but single-asset micro-cap with early-stage pipeline caps upside.
- ▹Phase 2 immunology candidate with no regulatory clarity or commercial validation; high risk of failure.
High Risk · 42/100Jul 14, 3:01 AM EDT
Erasca Upsizes Public Offering to $550M, Prices Shares at $17.50
ERAS
Erasca (ERAS) priced an upsized public offering of 31.43 million shares at $17.50 per share, raising $550 million. The offering was increased from an initial $500 million target, providing the company with additional capital for its pipeline development.
- ▹Dilution risk from large upsized offering
- ▹Single-asset company with no approved products
High Risk · 37/100Jul 14, 8:11 AM EDT
Inhibikase Therapeutics Raises $50M via Stock Sale to RA Capital
IKT
Inhibikase Therapeutics (IKT) sold 25 million shares to RA Capital Management for $50M through its ATM facility. The funds will support operations through the topline data readout of its Phase 3 IMPROVE-PAH study. Shares fell over 9% in pre-market trading.
- ▹Dilution risk from $50M ATM offering, shares down 9%
- ▹Single-asset micro-cap with no commercial product, runway extended to Phase 3 readout
High Risk · 27/100Jul 14, 7:10 AM EDT
NextCure to Merge with Avere in All-Stock Deal, Raises $320M
NXTCHNSPF
NextCure (NXTC) announced an all-stock reverse merger with privately held Avere Therapeutics, a biotech focused on inflammatory diseases. The deal includes a concurrent $320M private placement. Shares surged over 200% premarket on the news.
- ▹Reverse merger with no approved products or clear regulatory path; single-asset micro-cap with high dilution risk from $320M PIPE.